{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:08:15Z","timestamp":1774397295143,"version":"3.50.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>A lung transplant patient with invasive aspergillosis (IA) manifested symptoms of voriconazole-induced transaminitis with systemic voriconazole and progression of IA after switching to oral posaconazole. With limited options for standard triazole therapy, aerosolized delivery with one of the second-generation triazoles was considered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>Feasibility for aerosolized delivery was evaluated using cascade impactor and analysis of physicochemical characteristics of voriconazole (10\u2009mg\/mL) and posaconazole (6, 12\u2009mg\/mL) solutions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Both triazoles showed favorable characteristics for aerosol delivery with mass median aerodynamic diameter, geometric standard deviation, respirable fraction (&lt;5.4 \u00b5m) of 2.8 \u00b5m, 2.0, 86%; 3.4 \u00b5m, 2.4, 78%; and 3.0 \u00b5m, 2.3, 79% for voriconazole and 6, 12\u2009mg\/mL of posaconazole, respectively. <jats:italic toggle=\"yes\">Aspergillus fumigatus<\/jats:italic> isolate from the patient was more susceptible to voriconazole, and hence aerosolized voriconazole was introduced around the third month posttransplant at 40\u2009mg TID for 1 week, 40\u2009mg BID for 1 week, followed by 40\u2009mg daily thereafter, along with IV caspofungin (50\u2009mg\/d) and liposomal amphotericin B (300\u2009mg\/d). The aerosol regimen was well tolerated by the patient with undetectable trough plasma levels of voriconazole. Bronchoscopy at the fourth month revealed improvement in anastomotic plaques with reduction in bronchoalveolar lavage galactomannan values (7.48\u20132.15\u2009ng\/mL). This consolidated aerosolized and intravenous regimen was maintained until 2.97 years posttransplant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>The intravenous solutions of both second-generation triazoles showed characteristics that were suitable for aerosol delivery. Our report further adds to the therapeutic experience with the use of aerosolized voriconazole for IA in a lung transplant patient.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000002697","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T22:09:04Z","timestamp":1564006144000},"page":"2608-2613","source":"Crossref","is-referenced-by-count":9,"title":["Aerosolization of Second-generation Triazoles: In Vitro Evaluation and Application in Therapy of Invasive Airway Aspergillosis"],"prefix":"10.1097","volume":"103","author":[{"given":"Harisudhan","family":"Thanukrishnan","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy E.","family":"Corcoran","sequence":"additional","affiliation":[{"name":"Department of Chemical and Petroleum Engineering, University of Pittsburgh, Pittsburgh, PA."},{"name":"Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA."},{"name":"Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo J.","family":"Iasella","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cody A.","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Nero","sequence":"additional","affiliation":[{"name":"Department of Chemical and Petroleum Engineering, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Morrell","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"McDyer","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahid","family":"Hussain","sequence":"additional","affiliation":[{"name":"Multi-Organ Transplant Program, Division of Infectious Diseases, Transplant Infectious Diseases, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Hong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raman","family":"Venkataramanan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA."},{"name":"Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Ensor","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA."},{"name":"Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20231002","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/TP.0000000000001050","article-title":"Antifungal prophylaxis in lung transplant recipients.","volume":"100","author":"Patel","year":"2016","journal-title":"Transplantation"},{"key":"R2-20231002","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12281-014-0199-5","article-title":"Recent developments in inhaled triazoles against invasive pulmonary aspergillosis.","volume":"8","author":"Merlos","year":"2014","journal-title":"Curr Fungal Infect Rep"},{"key":"R3-20231002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1155\/2010\/580197","article-title":"Clinical manifestations of hyper IgE syndromes.","volume":"29","author":"Freeman","year":"2010","journal-title":"Dis Markers"},{"key":"R4-20231002","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.healun.2016.01.007","article-title":"The 2015 International Society for Heart And Lung Transplantation guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: executive summary.","volume":"35","author":"Husain","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"R5-20231002","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/cid\/ciw444","article-title":"Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America.","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R6-20231002","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1183\/09031936.00163511","article-title":"Remarkably efficient inhaled antifungal monotherapy for invasive pulmonary aspergillosis.","volume":"40","author":"Hilberg","year":"2012","journal-title":"Eur Respir J"},{"key":"R7-20231002","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jcf.2013.10.014","article-title":"Nebulized voriconazole in infections with scedosporium apiospermum\u2013case report and review of the literature.","volume":"13","author":"Holle","year":"2014","journal-title":"J Cyst Fibros"},{"key":"R8-20231002","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ajt.14580","article-title":"Salvage therapy with topical posaconazole in lung transplant recipients with invasive scedosporium infection.","volume":"18","author":"Sol\u00e9","year":"2018","journal-title":"Am J Transplant"},{"key":"R9-20231002","first-page":"597","article-title":"Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung.","volume":"45","author":"Dolovich","year":"2000","journal-title":"Respir Care"},{"key":"R10-20231002","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0021-8502(86)90035-2","article-title":"Deposition of particles in the human respiratory tract in the size range of 0.005\u201315 micron.","volume":"17","author":"Heyder","year":"1986","journal-title":"J Aerosol Sci"},{"key":"R11-20231002","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1592\/phco.30.6.562","article-title":"Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists.","volume":"30","author":"Le","year":"2010","journal-title":"Pharmacotherapy"},{"key":"R12-20231002","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1592\/phco.20.3.166.34783","article-title":"Aerosolized antimicrobial therapy in acutely ill patients.","volume":"20","author":"Wood","year":"2000","journal-title":"Pharmacotherapy"},{"key":"R13-20231002","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa073687","article-title":"STAT3 mutations in the hyper-IgE syndrome.","volume":"357","author":"Holland","year":"2007","journal-title":"N Engl J Med"},{"key":"R14-20231002","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMe078197","article-title":"STAT3 signaling and the hyper-IgE syndrome.","volume":"357","author":"Levy","year":"2007","journal-title":"N Engl J Med"},{"key":"R15-20231002","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1469-0691.2008.02086.x","article-title":"Technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds.","volume":"14","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"R16-20231002","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1128\/AAC.01141-13","article-title":"In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.","volume":"57","author":"Gregson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20231002","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1128\/AAC.00514-12","article-title":"Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus.","volume":"56","author":"Tashiro","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-20231002","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1111\/j.1600-6143.2006.01529.x","article-title":"Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients.","volume":"6","author":"Corcoran","year":"2006","journal-title":"Am J Transplant"},{"key":"R21-20231002","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1086\/521174","article-title":"Lack of cross-hepatotoxicity between voriconazole and posaconazole.","volume":"45","author":"Foo","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R22-20231002","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/IDR.S154457","article-title":"Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis.","volume":"11","author":"Mart\u00ednez-Casanova","year":"2018","journal-title":"Infect Drug Resist"},{"key":"R23-20231002","first-page":"652","article-title":"Drug properties affecting aerosol behavior.","volume":"45","author":"Suarez","year":"2000","journal-title":"Respir Care"},{"key":"R24-20231002","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejpb.2008.12.014","article-title":"Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution.","volume":"72","author":"Tolman","year":"2009","journal-title":"Eur J Pharm Biopharm"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:17:48Z","timestamp":1696223868000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002697","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}